|
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Clinical research trials and Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon. Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon  Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
For Condition: Leukemia,Multiple Myeloma,Lymphoma,Testicular Cancer,ovarian epithelial cancer,kidney tumor,Breast Cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Fred Hutchinson Cancer Research Center
Synopsis: RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the esophagus , stomach, small intestine, or colon.
Details: OBJECTIVES: I. Determine the frequency of treatment success of beclomethasone in patients with intestinal graft-versus-host disease with contraindications to high-dose immunosuppressive therapy. II. Determine the frequency of adverse events related to the use of this drug in these patients. III. Assess the natural history and outcome of the medical problem for which high-dose immunosuppressive therapy was a contraindication. PROTOCOL OUTLINE: Patients receive oral beclomethasone 4 times daily for 28 days. Treatment may repeat for an additional 28 days as needed. Patients are interviewed weekly to assess treatment success and adverse events. Patients are followed at 1 and 2 weeks. PROJECTED ACCRUAL: A total of 40-100 patients will be accrued for this study within 3 years.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: /
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven intestinal (esophagus, stomach, small intestine, or colon) graft-versus-host disease (GVHD) exhibiting symptoms such as nausea, vomiting, anorexia, diarrhea, or abdominal pain in the absence of another explanation for these symptoms - Specific contraindications to high-dose immunosuppressive therapy, such as: Recurrent malignant disorder for which an allogeneic antitumor effect is desired; Aspergillus or other fungal infection; Severe myopathy, hyperglycemia, bone problems, or neuropsychiatric symptoms related to corticosteroid use; Thrombotic thrombocytopenic purpura or hemolytic uremic syndrome related to immunosuppressive therapy; Epstein-Barr virus-related immunoproliferative disease - No GVHD unresponsive to previous high-dose immunosuppressive therapy - No concurrent infections involving the intestinal tract such as: Salmonella; Shigella; Clostridium difficile (toxin positive); Rotavirus Giardia lamblia; Cytomegalovirus by shell vial culture --Prior/Concurrent Therapy-- - Biologic therapy: At least 7 days since prior anti-thymocyte globulin or other immunosuppressive agents, including investigational agents - Chemotherapy: Concurrent cyclosporine, methotrexate, tacrolimus, mycophenolate mofetil, or prednisone allowed if plan in place to taper or discontinue - Endocrine therapy: Not specified - Radiotherapy: Not specified - Surgery: Not specified - Other: At least 24 hours since prior drugs that suppress gastric acid secretion (i.e., H2 receptor antagonists or omeprazole); No concurrent drugs that suppress gastric acid secretion --Patient Characteristics-- - Age: Not specified - Performance status: Not specified - Life expectancy: Not specified - Hematopoietic: Adequate platelet count - Hepatic: Not specified - Renal: Not specified - Other: Able to swallow oral capsules; No persistent vomiting of all oral intake; No multiorgan failure; No sepsis syndrome, including positive bacterial or fungal cultures within 72 hours of study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
DavidHockenbery, Study Chair, Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109
United States
Additional Information:
Study ID Numbers: CDR0000068475; FHCRC-1500.00,NCI-H01-0067
Study Start Date: July 2000
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00010283
Other Kidney Tumor Studies:
1. PS-341 in Treating Patients With Hematologic Cancer
2. Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
3. Combination Chemotherapy in Treating Patients With Lymphoma
4. Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
5. Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
Related Studies:
Other kidney tumor Clinical Trials
Other Washington Clinical Trials
Other Seattle Clinical Trials
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
|
|
|
|
|
|
|
|
